Filing Flows › Comparisons › EVFM vs TVRD
Evofem Biosciences vs Tvardi Therapeutics: EVFM and TVRD compared
Evofem Biosciences is the larger company: $2.6M of revenue in its latest quarter (Q2 2026) against $2.6M for Tvardi Therapeutics (Q1 2025). Tvardi Therapeutics is growing faster (+20% against -45% a year earlier). Tvardi Therapeutics is more profitable, with an operating margin of -92.9% against -94.5%.
Where the money goes: EVFM and TVRD
Evofem Biosciences (EVFM) · Q2 2026
Evofem Biosciences, Q2 2026: revenue $2.6M (-45% year over year), operating margin -94.5%, net loss $11.0M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
Tvardi Therapeutics (TVRD) · Q1 2025
Tvardi Therapeutics, Q1 2025: revenue $2.6M (+20% year over year), operating margin -92.9%, net loss $4.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Evofem Biosciences (EVFM) | Tvardi Therapeutics (TVRD) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2025 |
| Revenue | $2.6M | $2.6M |
| Revenue growth, Y/Y | -45% | +20% |
| Operating margin | -94.5% | -92.9% |
| Net earnings | −$11.0M | −$4.9M |
| Net margin | -419.1% | -191.0% |
| Operating cash flow | −$3.1M | −$4.7M |
Where the revenue comes from
Tvardi Therapeutics
- Other revenue: $1.3M (51%)
- Collaborative revenue: $1.2M (47%)
- Clinical compound revenue: $48K (2%)
Questions
Which is bigger, Evofem Biosciences or Tvardi Therapeutics?
Evofem Biosciences is the larger company: $2.6M of revenue in its latest quarter (Q2 2026) against $2.6M for Tvardi Therapeutics (Q1 2025).
Is Evofem Biosciences or Tvardi Therapeutics growing faster?
Tvardi Therapeutics is growing faster (+20% against -45% a year earlier).
Which is more profitable, Evofem Biosciences or Tvardi Therapeutics?
Tvardi Therapeutics is more profitable, with an operating margin of -92.9% against -94.5%.
More: Evofem Biosciences earnings · how Evofem Biosciences makes money · Tvardi Therapeutics earnings · how Tvardi Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed May 13, 2025). Fiscal quarters can end on different dates. Not investment advice.